Cargando…

PD-L1: expression regulation

Programmed death-ligand 1 (PD-L1), expressed on the surface of tumor cells, can bind to programmed cell death-1 (PD-1) on T cells. The interaction of PD-1 and PD-L1 can inhibit T-cell responses by decreasing T-cell activity and accelerating their apoptosis. Various cancers express high levels of PD-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yu-Jie, Li, Guoli, Wang, Jiyin, Liu, Mengyuan, Wang, Zihan, Song, Yu, Zhang, Xulong, Wang, Xi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205351/ https://www.ncbi.nlm.nih.gov/pubmed/37228770 http://dx.doi.org/10.1097/BS9.0000000000000149

Ejemplares similares

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

Epigenetic Regulation of NK Cell-Mediated Antitumor Immunity
por: Xia, Miaoran, et al.
Publicado: (2021)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Current insight into the regulation of PD-L1 in cancer
por: Liu, Zhuandi, et al.
Publicado: (2022)

Regulation of PD-L1 expression in the tumor microenvironment
por: Yi, Ming, et al.
Publicado: (2021)

Regulation of PD-L1 Expression by Nuclear Receptors
por: Kiriyama, Yoshimitsu, et al.
Publicado: (2023)

PD-L1 expression in human cancers and its association with clinical outcomes
por: Wang, Xin, et al.
Publicado: (2016)

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
por: Xiao, Gang, et al.
Publicado: (2019)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
por: Gao, Feng, et al.
Publicado: (2019)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
por: Wang, Jiting, et al.
Publicado: (2021)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer
por: Zhang, Chenlu, et al.
Publicado: (2018)

Recent Findings in the Posttranslational Modifications of PD-L1
por: Li, Shu-Man, et al.
Publicado: (2020)

PD-L1 expression is regulated by ATP-binding of the ERBB3 pseudokinase domain
por: Li, Yamu, et al.
Publicado: (2022)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
por: Sun, Jin-Yu, et al.
Publicado: (2020)

Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
por: Sun, Chengliang, et al.
Publicado: (2022)

PD-L1 Expression in Mastocytosis
por: Williams, Margaret, et al.
Publicado: (2019)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
por: Jiang, Mengzhen, et al.
Publicado: (2023)

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
por: Tian, Lingyu, et al.
Publicado: (2020)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
por: Jiang, Xianjie, et al.
Publicado: (2019)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
por: Garcia-Diaz, Angel, et al.
Publicado: (2017)

Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment
por: Wang, Rui-Bin, et al.
Publicado: (2020)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors
por: Fu, Yujie, et al.
Publicado: (2020)

PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
por: Song, Minmin, et al.
Publicado: (2013)

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
por: Wang, Tao, et al.
Publicado: (2022)

TET2 Inhibits PD-L1 Gene Expression in Breast Cancer Cells through Histone Deacetylation
por: Shen, Yinghui, et al.
Publicado: (2021)

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
por: Wang, Jun, et al.
Publicado: (2017)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
por: Sun, Chenglong, et al.
Publicado: (2020)

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells
por: Dong, Ling, et al.
Publicado: (2016)

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

Glial and Vascular Cell Regulation of the Blood-Brain Barrier in Diabetes
por: Li, Xiaolong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b73ou74sn2e4berablj6ehoqf6